Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomized, double-blind, placebo-controlled phase 2 trial

M. R. Rigby, L. A. DiMeglio, M. S. Rendell, E. I. Felner, J. M. Dostou, S. E. Gitelman, C. M. Patel, K. J. Griffin, E. Tsalikian, P. A. Gottlieb, C. J. Greenbaum, N. A. Sherry, W. V. Moore, R. Monzavi, S. M. Willi, Philip Raskin, A. Moran, W. E. Russell, A. Pinckney, L. Keyes-ElsteinM. Howell, S. Aggarwal, N. Lim, D. Phippard, G. T. Nepom, J. McNamara, M. R. Ehlers

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)S81-S82
JournalDiabetes Technology and Therapeutics
StatePublished - Feb 1 2015

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this